Psilocybin before chemotherapy protected nerves in mice

Two doses of a compound associated with “magic mushrooms” were given before chemotherapy, and mice were largely protected from the peripheral nerve damage normally caused by treatment. Psilocybin before chemotherapy did more than alter pain-related responses: it helped preserve the sensory nerve endings themselves. The study was published in Science.

Peripheral nerve damage is a common and sometimes long-lasting complication of several widely used anticancer drugs. Patients can experience tingling, numbness, burning pain, hypersensitivity or loss of sensation, usually beginning in the hands and feet. The condition is known as chemotherapy-induced peripheral neuropathy, or CIPN. In severe cases, it can force physicians to reduce a chemotherapy dose or change treatment.

The researchers asked whether psilocybin might be more useful before that damage occurs, acting as a neuroprotective agent rather than simply suppressing symptoms afterward.

Two doses before treatment

The experiments involved mice, including tumor-bearing animals. Psilocybin was administered before chemotherapy; in one of the main regimens, the animals received two doses of 1 mg per kilogram one week apart.

The mice were then treated with chemotherapy drugs known to cause peripheral neuropathy, including cisplatin, paclitaxel and docetaxel.

Untreated animals developed changes in paw sensitivity and lost fine sensory nerve endings in the skin. Mice pretreated with psilocybin showed substantially less of this damage, and in several experiments neuropathy was prevented. Protection was observed with different classes of chemotherapy and persisted in experiments involving repeated treatment cycles.

A critical finding was that psilocybin did not reduce the antitumor activity of chemotherapy in tumor-bearing mice. Any proposed protective treatment in oncology must clear this hurdle: preserving normal tissue would be of little value if it also protected the tumor.

Keeping mitochondria moving

The mechanistic findings are perhaps the most striking part of the study.

Sensory neurons can extend over very long distances. Their axons therefore need a continuous supply of mitochondria, the cellular structures that generate much of the energy required for nerve function.

Mitochondria can be thought of as mobile power stations. They are transported along axons toward distant nerve endings. When that transport fails, the farthest parts of the neuron can become energy-deprived and eventually degenerate.

The experiments showed that chemotherapy disrupted mitochondrial movement and distribution in sensory neurons. Psilocybin helped preserve that trafficking and maintained mitochondria in vulnerable regions of the nerve fibers.

The effect involved the serotonin 5-HT2A receptor, a receptor also central to many of psilocybin's better-known actions. Activating this receptor initiated intracellular signaling that ultimately supported the molecular machinery responsible for moving mitochondria along the axon. Blocking parts of this pathway weakened the protective effect.

Elements of the proposed mechanism were also examined in human nerve cells and human neural tissue in laboratory experiments, providing additional support for its biological relevance.

Neuroprotection without a psychedelic experience?

The researchers also tested tabernanthalog, a related compound that acts on a similar receptor system but lacks the characteristic hallucinogenic effects associated with psilocybin. It also protected sensory nerves in the animals.

That does not establish that psychedelic and neuroprotective effects can be fully separated in humans. It does suggest, however, that the subjective psychedelic state itself is probably not required for the peripheral nerve-protection mechanism observed in these experiments.

The study also detected changes in brain activity associated with chemotherapy-induced neuropathy and partial normalization after psilocybin treatment. But the central claim of the paper is prevention of nerve injury, not treatment of established chronic pain.

That distinction matters. Psilocybin was administered before chemotherapy. The experiments were not designed to show that it can repair nerves that have already been damaged or relieve symptoms in patients who already have CIPN.

There is also a much larger translational limitation: the evidence for efficacy comes primarily from mice. Finding related mechanisms in human nerve cells does not establish clinical benefit. Researchers still need to determine an appropriate dose, treatment schedule, safety profile, interactions with cancer therapy and whether the effect can actually prevent neuropathy in patients.

The broader implication is nevertheless unusual. A molecule studied mainly for its effects on the brain and mental states appears, in this work, to protect peripheral nerves through a much more physical process: keeping their mitochondrial energy supply moving to where it is needed.